PDCD1 and melanoma: We then applied the SC-2 gene signature to five melanoma immunotherapy datasets, including 263 samples with anti-PD1 or anti-CTLA4 therapies, and found that a higher gene signature score was not only significantly associated with better responses (Figure 5G), but was also significantly associated with better survival under immunotherapy (Figure 5H).